Novonesis stock gains 1.13 percent as buyback starts

Novonesis stock gained 1.13 percent to DKK 443.30 on Nasdaq Copenhagen on September 24, 2026, placing the shares 0.56 percent below the 52-week high of DKK 445.80. The move came as the biosolutions group advanced its EUR 1 billion multi-year share buyback program.

Buyback program reaches the market

Via Ritzau reported on September 14, 2026, that Novonesis had started the first tranche of the buyback. The tranche allows purchases of B shares for up to EUR 75 million and is scheduled to run no later than December 17, 2026.

The program gives the company a recurring source of share demand while also supporting employee incentive obligations. Its maximum daily purchase volume is capped at 25 percent of the average trading volume over the preceding 20 business days, according to the release.

H1 growth reaches 8 percent

Novonesis reported 8 percent organic sales growth in the first half of 2026, while adjusted EBITDA margin reached 37.7 percent. The company raised its full-year organic growth outlook to 7 percent to 8 percent from 5 percent to 7 percent, and expects adjusted EBITDA margin at the upper end of its 37 percent to 38 percent range, Securities.io reported.

That combination matters because the outlook improvement is paired with a margin target near 38 percent, giving investors two measurable operating markers for 2026. Novonesis also approved an interim dividend of DKK 2.35 per share for the first half of the year.

Analyst target remains higher

JPMorgan named Novonesis its top long in European chemicals on September 24, 2026, citing the company's structural organic growth profile and more than 20 percent post-tax return on invested capital, Investing.com reported. The reference price at DKK 443.30 therefore sits close to the yearly high, while the buyback and raised guidance provide separate company-specific supports for the valuation discussion.

Stock stays near yearly high

Novonesis stock stood at DKK 443.30 on Nasdaq Copenhagen on September 24, 2026, up 1.13 percent on the session. The stock's 52-week range was DKK 437.50 to DKK 445.80, and market capitalization was DKK 123,193,512,857 on the same date.